Response to dabrafenib plus trametinib on a rare BRAF mutation (V600_W604 deletion-insertion R) in an advanced non-small cell lung cancer patient

Akiko Tamura; Ryoko Inaba Higashiyama; Tatsuya Yoshida; Yaya Satozono; Yuichiro Ohe

doi:10.1111/1759-7714.15330

Response to dabrafenib plus trametinib on a rare BRAF mutation (V600_W604 deletion-insertion R) in an advanced non-small cell lung cancer patient

Thorac Cancer. 2024 May 20. doi: 10.1111/1759-7714.15330. Online ahead of print.

Authors

Akiko Tamura¹, Ryoko Inaba Higashiyama¹, Tatsuya Yoshida¹, Yaya Satozono¹, Yuichiro Ohe¹

Affiliation

¹ Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.

PMID: 38766698
DOI: 10.1111/1759-7714.15330

Abstract

Although dabrafenib plus trametinib has been approved for BRAF V600E mutation positive advanced non-small cell lung cancer (NSCLC), data on its efficacy against uncommon BRAF mutations are still limited due to their rare frequency. We report a case of 70-year-old woman with BRAF V600_W604 deletion-insertion R-positive stage IVA lung adenocarcinoma, who was successfully treated with dabrafenib plus trametinib. Herein, we discuss the oncogenic role of uncommon BRAF mutations and highlight the importance of performing comprehensive genomic profiling on patients without any targetable gene alterations in companion diagnostics.

Keywords: BRAF V600_W604 deletion–insertion R; BRAF mutation; comprehensive genomic profiling; dabrafenib plus trametinib; lung adenocarcinoma.

Publication types

Case Reports